[HTML] nih.gov

[HTML][HTML] Effectiveness and safety of toripalimab, camrelizumab, and sintilimab in a real-world cohort of hepatitis B virus associated hepatocellular carcinoma patients

J Chen, X Hu, Q Li, W Dai, X Cheng… - Annals of …, 2020 - ncbi.nlm.nih.gov
Background The clinical significance of programmed cell death protein-1 (PD-1)-targeted
immunotherapy in Chinese patients is understudied. We thus aimed to evaluate the safety …
被引用次数：45 相关文章
[PDF] amegroups.cn

[PDF][PDF] Effectiveness and safety of toripalimab, camrelizumab, and sintilimab in a real-world cohort of hepatitis B virus associated hepatocellular carcinoma patients

J Chen, X Hu, Q Li, W Dai, X Cheng, W Huang, W Yu… - 2020 - cdn.amegroups.cn
Background: The clinical significance of programmed cell death protein-1 (PD-1)-targeted
immunotherapy in Chinese patients is understudied. We thus aimed to evaluate the safety …

Effectiveness and safety of toripalimab, camrelizumab, and sintilimab in a real-world cohort of hepatitis B virus associated hepatocellular carcinoma patients.

J Chen, X Hu, Q Li, W Dai, X Cheng… - Annals of …, 2020 - europepmc.org
Background The clinical significance of programmed cell death protein-1 (PD-1)-targeted
immunotherapy in Chinese patients is understudied. We thus aimed to evaluate the safety …
[HTML] amegroups.org

[HTML][HTML] Effectiveness and safety of toripalimab, camrelizumab, and sintilimab in a real-world cohort of hepatitis B virus associated hepatocellular carcinoma patients

J Chen, X Hu, Q Li, W Dai, X Cheng… - Annals of …, 2020 - atm.amegroups.org
Background: The clinical significance of programmed cell death protein-1 (PD-1)-targeted
immunotherapy in Chinese patients is understudied. We thus aimed to evaluate the safety …

Effectiveness and safety of toripalimab, camrelizumab, and sintilimab in a real-world cohort of hepatitis B virus associated hepatocellular carcinoma patients

J Chen, X Hu, Q Li, W Dai, X Cheng… - Annals of …, 2020 - pubmed.ncbi.nlm.nih.gov
Background The clinical significance of programmed cell death protein-1 (PD-1)-targeted
immunotherapy in Chinese patients is understudied. We thus aimed to evaluate the safety …

[引用][C] Effectiveness and safety of toripalimab, camrelizumab, and sintilimab in a real-world cohort of hepatitis B virus associated hepatocellular carcinoma patients

J Chen, X Hu, Q Li, W Dai, X Cheng… - Annals of …, 2020 - atm.amegroups.org
Effectiveness and safety of toripalimab, camrelizumab, and sintilimab in a real-world cohort of
hepatitis B virus associated hepatocellular carcinoma patients - Chen - Annals of Translational …